AM
Ambalal Sarabhai Enterprises Ltd (AMBALALSA)
₹38.96
Mkt cap
₹296 Cr
P/E ratio
19.10
P/B
1.83
Div yield
0.00%
ROE
12.40%
ROCE
11.70%
EPS (TTM)
₹2.04
Book value
₹21
52W range
30–50
Sector
Healthcare
Price history
Previous close
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics [1]
NSE AMBALALSABSE 500009
Health check
Mixed
ValuationCheap
ProfitabilityAverage
GrowthLow
TechnicalsNeutral
52-week range
−22.05% from high₹39
₹30+29.22% from low₹50
Current
₹38.96
Prev close
₹39.14
Day
−0.46%
Price performance
1D
−0.46%
1W
+1.91%
1M
+6.92%
3M
−18.39%
6M
+18.96%
1Y
—
YTD
+20.06%
Financials
Revenue, profit & margin
P/E ratio
19.1×
AMBALALSA is 41% below the sector median of 32.5×
AMBALALSA19.1×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40.01 | 43.11 | 54.35 | 40.70 | 44.70 | 45.97 | 64.81 | 40.34 | 44.45 | 52.00 | 65.49 | 43.56 | 58.13 | |
| YoY Sales growth | -14.58% | +21.92% | +22.30% | +12.74% | +11.72% | +6.63% | +19.25% | -0.88% | -0.56% | +13.12% | +1.05% | +7.98% | +30.78% | |
| Expenses | 39.00 | 40.58 | 49.70 | 40.23 | 42.16 | 46.67 | 59.51 | 38.88 | 44.09 | 47.92 | 59.79 | 39.01 | 55.78 | |
| Operating Profit | 1.01 | 2.53 | 4.65 | 0.47 | 2.54 | -0.70 | 5.30 | 1.46 | 0.36 | 4.08 | 5.70 | 4.55 | 2.35 | |
| OPM % | 2.52% | 5.87% | 8.56% | 1.15% | 5.68% | -1.52% | 8.18% | 3.62% | 0.81% | 7.85% | 8.70% | 10.45% | 4.04% | |
| Other Income | 2.85 | 1.63 | 4.79 | 2.30 | 2.80 | 5.76 | -5.37 | 8.36 | 1.62 | 1.94 | 3.02 | 2.46 | 1.39 | |
| Interest | 0.92 | 0.99 | 0.90 | 0.95 | 1.22 | 1.14 | 0.96 | 1.01 | 0.96 | 0.70 | 1.42 | 0.98 | 1.04 | |
| Depreciation | 1.14 | 1.13 | 0.25 | 0.98 | 1.01 | 0.99 | 1.02 | 0.88 | 1.06 | 0.96 | 1.05 | 1.35 | 1.39 | |
| Profit before tax | 1.80 | 2.04 | 8.29 | 0.84 | 3.11 | 2.93 | -2.05 | 7.93 | -0.04 | 4.36 | 6.25 | 4.68 | 1.31 | |
| Tax % | 40.00% | 34.31% | -8.69% | 59.52% | 15.76% | 23.89% | -86.83% | -3.66% | 1,300.00% | 16.51% | -4.00% | 14.96% | 48.85% | |
| Net Profit | 1.08 | 1.33 | 9.02 | 0.35 | 2.62 | 2.23 | -0.27 | 8.22 | -0.56 | 3.64 | 6.50 | 3.98 | 0.67 | |
| EPS in Rs | 0.14 | 0.17 | 1.18 | 0.05 | 0.34 | 0.29 | -0.04 | 1.07 | -0.07 | 0.47 | 0.85 | 0.52 | 0.09 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202631.36%Promoter
Promoters31.36%
FIIs0.00%
DIIs0.00%
Public68.62%0.02
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Ambalal Sarabhai | ₹38.31 | 19.14 | 296 | 0.00% | 1 | +219.64% | 58 | +30.78% | 11.69% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Nov - We hereby submit Newspaper Publication under Regulation 30 of SEBI (LODR), Regulations, 2015Results- Financial Results For Quarter And Half Year Ended 30.09.2026 5 NovBoard Meeting Outcome for We Hereby Submit Outcome Of Board Meeting Held On 05.11.2026 5 Nov - Board approved Q2/H1 FY2026-27 unaudited standalone and consolidated results on 5 Nov 2026.Board Meeting Intimation for Approval Of Financial Results For Quarter And Half Year Ended 30.09.2026 28 Oct - Board to meet on November 5, 2026, to approve Q2 FY27 unaudited results; trading window closed till November 7.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - We hereby submit Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018. Kindly take the same on your records.






